{"podcast":{"title":"Cell & Gene: The Podcast","slug":"cell-gene-the-podcast-4048431","podcast_index_feed_id":4048431,"rss_url":"https://rss.buzzsprout.com/1810482.rss","website_url":"https://www.buzzsprout.com/1810482","image_url":"https://storage.buzzsprout.com/f3p8rfd9kizh4zywm5msg5goq7nu?.jpg","author":"Erin Harris","episode_count":140,"summary":"Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.","last_synced_at":"2026-06-18T18:19:19.741610+00:00","page_url":"https://stenobird.com/podcast/cell-gene-the-podcast-4048431"},"episode":{"title":"Why In Vivo Therapies Are Moving Toward the Clinic with Ascidian Therapeutics' Dr. Mike Ehlers","slug":"why-in-vivo-therapies-are-moving-toward-the-clinic-with-ascidian-therapeutics-dr-mike-ehlers","published_at":"2026-06-12T09:00:00+00:00","page_url":"https://stenobird.com/podcast/cell-gene-the-podcast-4048431/why-in-vivo-therapies-are-moving-toward-the-clinic-with-ascidian-therapeutics-dr-mike-ehlers","show_page_url":"https://stenobird.com/podcast/cell-gene-the-podcast-4048431","url":"https://www.buzzsprout.com/1810482/episodes/19318822-why-in-vivo-therapies-are-moving-toward-the-clinic-with-ascidian-therapeutics-dr-mike-ehlers.mp3","audio_url":"https://www.buzzsprout.com/1810482/episodes/19318822-why-in-vivo-therapies-are-moving-toward-the-clinic-with-ascidian-therapeutics-dr-mike-ehlers.mp3","summary":"We love to hear from our listeners. Send us a message. In Episode 3 of our in vivo-focused special series of Cell & Gene: The Podcast, Ascidian Therapeutics' Founder, President, and CEO Mike Ehlers, M.D., Ph.D., explains how the company is advancing a new class of genetic medicines built on RNA exon editing to durably correct disease at the transcript level without permanently altering DNA. He also shares why in vivo therapies still need to prove precision, durability, and predictability ...","meta_description":"We love to hear from our listeners. Send us a message. In Episode 3 of our in vivo-focused special series of Cell & Gene: The Podcast, Ascidian Therap…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1091,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/cell-gene-the-podcast-4048431/episodes/why-in-vivo-therapies-are-moving-toward-the-clinic-with-ascidian-therapeutics-dr-mike-ehlers/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/cell-gene-the-podcast-4048431/why-in-vivo-therapies-are-moving-toward-the-clinic-with-ascidian-therapeutics-dr-mike-ehlers.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}